Role of oxidative stress in angiotensin-induced hypertension

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 284, Issue 4 53-4, 2003, Pages

  Reckelhoff, Jane F ^a   Romero, J Carlos ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Endothelin; Isoprostanes; Renovascular hypertension; Sodium balance; Spontaneous hypertension

Indexed keywords

ANGIOTENSIN; ARACHIDONIC ACID; ENDOTHELIN; ISOPROSTANE; NITRIC OXIDE; SODIUM; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANGIOTENSIN BLOOD LEVEL; BIOAVAILABILITY; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW; SODIUM BALANCE; VASOCONSTRICTION;

EID: 0037384728     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00491.2002     Document Type: Review

References (195)

1. Abraham G and Simon G. Autopotentiation of pressor responses by subpressor angiotensin II in rats. Am J Hypertens 7: 269-275, 1994.
2. Alexander BT, Cockrell KL, Rinewalt AN, Herrington JN, and Granger JP. Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 280: R1388-R1392, 2001.
3. Alexander RW, Brock TA, Gimbrone MA Jr, and Rittenhouse SE. Angiotensin increases inositol trisphosphate and calcium in vascular smooth muscle. Hypertension 7: 447-451, 1985.
4. Ames RP, Borkowski AJ, Sicincki AM, and Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest 44: 1171-1186, 1965.
5. Ando K, Sato Y, Ito Y, Ogata E, and Fujita T. Effect of salt loading on aldosterone response to long-term infusion of angiotensin II in rats. J Cardiovasc Pharmacol 17: 386-389, 1991.
6. Antonaccio MJ, High JP, Rubin B, and Schaeffer T. Contribution of the kidneys but not adrenal glands to the acute antihypertensive effects of captopril in spontaneously hypertensive rats. Clin Sci (Lond) 57, Suppl 5: 127s-130s, 1979.
7. Awad JA, Roberts LJ II, Burk RF, and Morrow JD. Isoprostanes - prostaglandin-like compounds formed in vivo independently of cyclooxygenase: use as clinical indicators of oxidant damage. Gastroenterol Clin North Am 25: 409-427, 1996.
8. Bagi Z, Ungvari Z, and Koller A. Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. Arterioscler Thromb Vasc Biol 22: 28-33, 2002.
9. Bailie MD, Davis LE, and Loutzenhiser R. Intrarenal secretion of renin in the dog: effect of furosemide. Am J Physiol 224:425-430, 1973.
10. B receptor activation in angiotensin II-induced hypertension: effects of salt intake. Am J Physiol Heart Circ Physiol 281: H2218-H2225, 2001.
11. Ballew JR and Fink GD. Role of ETA receptors in experimental ANG II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol 281: R150-R154, 2001.
12. Baylis C, Harton P, and Engels K. Endothelial derived relaxing factor controls renal hemodynamics in the normal rat kidney. J Am Soc Nephrol 1: 875-881, 1990.
13. Beckman JS, Beckman TW, Chen J, Marshall PA, and Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87: 1620-1624, 1990.
14. Beharka AA, Wu D, Serafini M, and Meydani SN. Mechanism of vitamin E inhibition of cyclooxygenase activity in macrophages from old mice: role of peroxynitrite. Free Radic Biol Med 32: 503-511, 2002.
15. Beierwaltes WH, Arendshorst WJ, and Klemmer PJ. Electrolyte and water balance in young spontaneously hypertensive rats. Hypertension 4: 908-915, 1982.
16. Bell PD and Navar LG. Intrarenal feedback control of glomerular filtration rate. Semin Nephrol 2: 289-301, 1982.
17. Bergamaschi CT, Campos RR, and Lopes OU. Rostral ventrolateral medulla: a source of sympathetic activation in rats subjected to long-term treatment with L-NAME. Hypertension 34: 744-747, 1999.
18. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, and Webb RC. Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension 37: 781-786, 2001.
19. Bianchi G, Baldoli E, Lucca R, and Barbin P. Pathogenesis of arterial hypertension after the constriction of the renal artery leaving the opposite kidney intact both in the anaesthetized and in the conscious dog. Clin Sci (Colch) 42: 651-664, 1972.
20. Bouhnik J, Clauser E, Strosberg D, Frenoy JP, Menard J, and Corvol P. Rat angiotensinogen and des(angiotensin I)angiotensinogen: purification, characterization, and partial sequencing. Biochemistry 20: 7010-7015, 1981.
21. Braam B, Mitchell KD, Fox J, and Navar LG. Proximal tubular secretion of angiotensin II in rats. Am J Physiol Renal Fluid Electrolyte Physiol 264: F891-F898, 1993.
22. Brown AJ, Casals-Stenzel J, Gofford S, Lever AF, and Morton JJ. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am J Physiol Heart Circ Physiol 241: H381-H388, 1981.
23. Brown JJ, Davies DL, Morton JJ, Robertson JI, Cuesta V, Lever AF, Padfield PL, and Trust P. Mechanism of renal hypertension. Lancet 1: 1219-1221, 1976.
24. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, and Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441-449, 1972.
25. Bunkenburg B, Schnell C, Baum HP, Cumin F, and Wood JM. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences. Hypertension 18: 278-288, 1991.
26. Burnett JC Jr and Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol Renal Fluid Electrolyte Physiol 238: F279-F282, 1980.
27. Campbell DJ and Valentijn AJ. Identification of vascular renin-binding proteins by chemical cross-linking: inhibition of binding of renin by renin inhibitors. J Hypertens 12: 879-890, 1994.
28. Caravaggi AM, Bianchi G, Brown JJ, Lever AF, Morton JJ, Powell-Jackson JD, Robertson JI, and Semple PF. Blood pressure and plasma angiotensin II concentration after renal artery constriction and angiotensin infusion in the dog. (5-Isoleucine)angiotensin II and its breakdown fragments in dog blood. Circ Res 38: 315-321, 1976.
29. Cargill RI, Coutie WJ, and Lipworth BJ. The effects of angiotensin II on circulating levels of natriuretic peptides. Br J Clin Pharmacol 38: 139-142, 1994.
30. Chen X, Touyz RM, Park JB, and Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 38: 606-611, 2001.
31. Cheng TH, Shih NL, Chen SY, Loh SH, Cheng PY, Tsai CS, Liu SH, Wang DL, and Chen JJ. Reactive oxygen species mediate cyclic strain-induced endothelin-1 gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in endothelial cells. J Mol Cell Cardiol 33: 1805-1814, 2001.
32. Chi MS, Jones AW, and Freeman RH. Increased arterial potassium transport in reduced renal mass hypertension of the rat. Proc Soc Exp Biol Med 182: 229-236, 1986.
33. Cooke CL and Davidge ST. Peroxynitrite increases iNOS through NF-κB and decreases prostacyclin synthase in endothelial cells. Am J Physiol Cell Physiol 282: C395-C402, 2002.
34. Csiky B and Simon G. Synergistic vascular effects of dietary sodium supplementation and angiotensin II administration. Am J Physiol Heart Circ Physiol 273: H1275-H1282, 1997.
35. DeClue JW, Guyton AC, Cowley AW Jr, Coleman TG, Norman RA Jr, and McCaa RE. Subpressor angiotensin infusion, renal sodium handling, and salt-induced hypertension in the dog. Circ Res 43: 503-512, 1978.
36. DiBona GF. Nervous kidney: interaction between renal sympathic nerves and the renin-angiotensin system in the control of renal function. Hypertension 36: 1083-1088, 2000.
37. Dickinson CJ and Lawrence JR. A slowly developing pressor response to small concentrations of angiotensin: its bearing on the pathogenesis of chronic renal hypertension. Lancet I: 1354-1356, 1963.
38. Dickinson CJ and Yu R. Mechanism involved in the progressive pressor response to very small amounts of angiotensin in conscious rabbits. Circ Res XX and XXI: II-157-163, 1967.
39. Ding Y, Gonick HC, and Vaziri ND. Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am J Hypertens 13: 552-555, 2000.
40. Dobrian AD, Schriver SD, and Prewitt RL. Role of angiotensin II and free radicals in blood pressure regulation in a rat model of renal hypertension. Hypertension 38: 361-366, 2001.
41. Donnelly R, Elliott HL, and Meredith PA. Antihypertensive drugs: individualized analysis and clinical relevance of kinetic-dynamic relationships. Pharmacol Ther 53: 67-79, 1992.
42. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, and Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun 269: 713-717, 2000.
43. Dzau VJ. Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors. Am J Med 84: 4-8, 1988.
44. Elijovich F and Laffer CL. Participation of renal and circulating endothelin in salt-sensitive essential hypertension. J Hum Hypertens 16: 459-467, 2002.
45. Fink GD. Long-term sympatho-excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Clin Exp Pharmacol Physiol 24: 91-95, 1997.
46. Fukunaga M, Yura T, and Badr KF. Stimulatory effect of 8-Epi-PGF2 alpha, an F2-isoprostane, on endothelin-1 release. J Cardiovasc Pharmacol 26: S51-S52, 1995.
47. Gaboury CL, Simonson DC, Seely EW, Hollenberg NK, and Williams GH. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest 94: 2295-2300, 1994.
48. Gandhi SK, Gainer J, King D, and Brown NJ. Gender affects renal vasoconstrictor response to Ang I and Ang II. Hypertension 31: 90-96, 1998.
49. Gavras H, Brunner HB, Vaughan ED, and Laragh JH. Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 180: 1369-1371, 1973.
50. Gillies LK, Lu M, Wang H, and Lee RM. AT1 receptor antagonist treatment caused persistent arterial functional changes in young spontaneously hypertensive rats. Hypertension 30: 1471-1478, 1997.
51. Gomez RA, Chevalier RL, Everett AD, Peach MJ, and Carey RM. Renin gene-expression during salt depletion (Abstract). Kidney Int 35: 300A, 1989.
52. Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA Jr, and Alexander RW. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 261: 5901-5906, 1986.
53. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, and Norman RA Jr. Arterial pressure regulation overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52: 584-594, 1972.
54. Haas JA, Krier JD, Bolterman RJ, Juncos LA, and Romero JC. Low-dose angiotensin II increases free isoprostane levels in plasma. Hypertension 34: 983-986, 1999.
55. Hall JE, Granger JP, Hester RL, Coleman TG, Smith MJ Jr, and Cross RB. Mechanisms of escape from sodium retention during angiotensin II hypertension. Am J Physiol Renal Fluid Electrolyte Physiol 246: F627-F634, 1984.
56. Harrap SB, Nicolaci JA, and Doyle AE. Persistent effects on blood pressure and renal haemodynamics following chronic angiotensin converting enzyme inhibition with perindopril. Clin Exp Pharmacol Physiol 13: 753-765, 1986.
57. Harris PJ and Navar LG. Tubular transport responses to angiotensin. Am J Physiol Renal Fluid Electrolyte Physiol 248: F621-F630, 1985.
58. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, and Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 25: 1954-1962, 2002.
59. Hollenberg NK, Chenitz WR, Adams DF, and Williams GH. Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. J Clin Invest 54: 34-42, 1974.
60. Hricik DE. Angiotensin-converting enzyme inhibition in renovascular hypertension: the narrowing gap between functional renal failure and progressive renal atrophy. J Lab Clin Med 115: 8-9, 1990.
61. Hu L, Catanzaro DF, Pitarresi TM, Laragh JH, and Sealey JE. Identical hemodynamic and hormonal responses to 14-day infusions of renin or angiotensin II in conscious rats. J Hypertens 16: 1285-1298, 1998.
62. Huang WC, Bell PD, Harvey D, Mitchell KD, and Navar LG. Angiotensin influences on tubuloglomerular feedback mechanism in hypertensive rats. Kidney Int 34: 631-637, 1988.
63. Huang WC, Ploth DW, and Navar LG. Angiotensin-mediated alterations in nephron function in Goldblatt hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 243: F553-F560, 1982.
64. Hunt MK, Ramos SP, Geary KM, Norling LL, Peach MJ, Gomez RA, and Carey RM. Colocalization and release of angiotensin and renin in renal cortical cells. Am J Physiol Renal Fluid Electrolyte Physiol 263: F363-F373, 1992.
65. Ichihara A, Hayashi M, Hirota N, and Saruta T. Superoxide inhibits neuronal nitric oxide synthase influences on afferent arterioles in spontaneously hypertensive rats. Hypertension 37: 630-634, 2001.
66. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J 3: 31-36, 1989.
67. Inagami T, Mizuno K, Naruse K, Okamura T, and Kawamura M. Intracellular formation and release of angiotensins from juxtaglomerular cells. Kidney Int Suppl 30: S33-S37, 1990.
68. Ingelfinger JR, Pratt RE, Ellison K, and Dzau VJ. Sodium regulation of angiotensinogen mRNA expression in rat kidney cortex and medulla. J Clin Invest 78: 1311-1315, 1986.
69. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, and Dzau VJ. In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. J Clin Invest 85: 417-423, 1990.
70. Ishii K, Chang B, Kerwin JF Jr, Wagenaar FL, Huang ZJ, and Murad F. Formation of endothelium-derived relaxing factor in porcine kidney epithelial LLC-PK1 cells: an intra- and intercellular messenger for activation of soluble guanylate cyclase. J Pharmacol Exp Ther 256: 38-43, 1991.
71. Ito S, Arima S, Ren YL, Juncos LA, and Carretero OA. Endothelin-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 91: 2012-2019, 1993.
72. Joint National Committee. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med 153: 154-183, 1993.
73. Kanagy NL and Fink GD. Losartan prevents salt-induced hypertension in reduced renal mass rats. J Pharmacol Exp Ther 265: 1131-1136, 1993.
74. Kanagy NL, Pawloski CM, and Fink GD. Role of aldosterone in angiotensin II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol 259: R102-R109, 1990.
75. Keen HL, Brands MW, Smith MJ Jr, Shek EW, and Hall JE. Thromboxane is required for full expression of angiotensin hypertension in rats. Hypertension 29: 310-314, 1997.
76. Kerr S, Brosnan MJ, McIntyre M, Reid JL, Dominiczak AF, and Hamilton CA. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension 33: 1353-1358, 1999.
77. Kitamoto S, Egashira K, Kataoka C, Usui M, Koyanagi M, Takemoto M, and Takeshita A. Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J Hypertens 18: 1795-1800, 2000.
78. Krieger JE and Cowley AW Jr. Prevention of salt angiotensin II hypertension by servo control of body water. Am J Physiol Heart Circ Physiol 258: H994-H1003, 1990.
79. 2α in normal and hypercholesterolemic pigs. Am J Physiol Regul Integr Comp Physiol 283: R303-R308, 2002.
80. Krukoff TL. Central regulation of autonomic function: no brakes? Clin Exp Pharmacol Physiol 25: 474-478, 1998.
81. Kuczera M, Hilgers KF, Lisson C, Ganten D, Hilgenfeldt U, Ritz E, and Mann JF. Local angiotensin formation in hindlimbs of uremic hypertensive and renovascular hypertensive rats. J Hypertens 9: 41-48, 1991.
82. G-monomethyl-L-arginine and L-arginine on acetylcholine renal response. Hypertension 15: 659-663, 1990.
83. G-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol Renal Fluid Electrolyte Physiol 261: F1033-F1037, 1991.
84. Laragh JH, Sealey JE, Buhler FR, Vaughan ED, Brunner HR, Gavras H, and Baer L. The renin axis and vasoconstriction volume analysis for understanding and treating renovascular and renal hypertension. Am J Med 58: 4-13, 1975.
85. Laragh JH, Sealey JE, Niarchos AP, and Pickering TG. The vasoconstriction-volume spectrum in normotension and in the pathogenesis of hypertension. Fed Proc 41: 2415-2423, 1982.
86. Lerman LO, Bentley MD, Fiksen-Olsen MJ, Strick DM, Ritman EL, and Romero JC. Pressure dependency of canine intrarenal blood flow within the range of autoregulation. Am J Physiol Renal Fluid Electrolyte Physiol 268: F404-F409, 1995.
87. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, and Romero JC. Increased oxidative stress in experimental renovascular hypertension. Hypertension 37: 541-546, 2001.
88. Lever AF and Peart WS. Renin and angiotensin-like activity in renal lymph. J Physiol 160: 548-563, 1962.
89. Majid DS, Godfrey M, and Navar LG. Pressure natriuresis and renal medullary blood flow in dogs. Hypertension 29: 1051-1057, 1997.
90. Marletta MA, Yoon PS, Iyengar R, Leaf CD, and Wishnok JS. Macrophage oxidation of L-arginine to nitrite and nitrate: nitric oxide is an intermediate. Biochemistry 27: 8706-8711, 1988.
91. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 17: 707-719, 1991.
92. Masaki Z, Ferrario CM, Bumpus FM, Bravo EL, and Khosla MC. The course of arterial pressure and the effect of Sar1-Thr8-angiotensin II in a new model of two-kidney hypertension in conscious dogs. Clin Sci Mol Med 52: 163-170, 1977.
93. Mattson DL, Lu S, and Cowley AW Jr. Role of nitric oxide in the control of the renal medullary circulation. Clin Exp Pharmacol Physiol 24: 587-590, 1997.
94. Mattson DL, Lu S, Nakanishi K, Papanek PE, and Cowley AW Jr. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol Heart Circ Physiol 266: H1918-H1926, 1994.
95. Mattson DL and Wu F. Nitric oxide synthase activity and isoforms in rat renal vasculature. Hypertension 35: 337-341, 2000.
96. McCord JM and Fridovich I. Superoxide dismutase, an enzymic function for erythrocuproin (hemocuproin). J Biol Chem 244:6056-6063, 1969.
97. McCord JM and Fridovich I. Superoxide dismutase: the first twenty years (1968-1988). Free Radic Biol Med 5: 363-369, 1988.
98. McCubbin JW, DeMoura RS, Page IH, and Olmsted F. Arterial hypertension elicited by subpressor amounts of angiotensin. Science 149: 1394-1395, 1965.
99. McIntyre M, Hamilton CA, Rees DD, Reid JL, and Dominiczak AF. Sex differences in the abundance of endothelial nitric oxide in a model of genetic hypertension. Hypertension 30:1517-1524, 1997.
100. Melaragno MG and Fink GD. Role of ANG II in hypertension produced by chronic inhibition of nitric oxide synthase in conscious rats. Am J Physiol Heart Circ Physiol 271: H806-H811, 1996.
101. Miller ED Jr, Samuels AI, Haber E, and Barger AC. Inhibition of angiotensin conversion and prevention of renal hypertension. Am J Physiol 228: 448-453, 1975.
102. Mitchell KD, Braam B, and Navar LG. Hypertensinogenic mechanisms mediated by renal actions of renin-angiotensin system. Hypertension 19: I18-I27, 1992.
103. Moffett RB. Purification of multiple forms of plasma angiotensinogen: molecular weight and charge heterogeneity. Biochim Biophys Acta 912: 1-8, 1987.
104. Mollnau H, Wendt M, Szocs K, Lassegue B, Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, Tsilimingas N, Walter U, Forstermann U, Meinertz T, Griendling K, and Munzel T. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90: E58-E65, 2002.
105. Moncada S, Palmer RM, and Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142, 1991.
106. Morrow JD, Harris TM, and Roberts LJ 2nd. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem 184: 1-10, 1990.
107. Morrow JD and Roberts LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 36: 1-21, 1997.
108. Muirhead EE, Leach BE, Davis JO, Armstrong FB Jr, Pitcock JA, and Brosius WL Jr. Pathophysiology of angiotensin-salt hypertension. J Lab Clin Med 85: 734-745, 1975.
109. Munoz JM, Braun-Menendez E, Faciolo JC, and Leloir F. The mechanism of renal hypertension. Am J Med 200: 608-618, 1940.
110. Nabika T, Velletri PA, Lovenberg W, and Beaven MA. Increase in cytosolic calcium and phosphoinositide metabolism induced by angiotensin II and [Arg]vasopressin in vascular smooth muscle cells. J Biol Chem 260: 4661-4670, 1985.
111. Navar LG, Bell PD, and Burke TJ. Role of a macula densa feedback mechanism as a mediator of renal autoregulation. Kidney Int Suppl 12: S157-S164, 1982.
112. Navar LG, Carmines PK, Huang WC, and Mitchell KD. The tubular effects of angiotensin II. Kidney Int Suppl 20: S81-S88, 1987.
113. Navar LG, and Harrison-Bernard LM. Intrarenal angiotensin II augmentation in angiotensin II dependent hypertension. Hypertens Res 23: 291-301, 2000.
114. Navar LG and Rosivall L. Contribution of the renin-angiotensin system to the control of intrarenal hemodynamics. Kidney Int 25: 857-868, 1984.
115. Nishiyama A, Seth DM, and Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 39: 129-134, 2002.
116. Ortiz MC, Manriquez MC, Romero JC, and Juncos LA. Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension 38: 655-659, 2001.
117. Ortiz MC, Sanabria E, Manriquez MC, Romero JC, and Juncos LA. Role of endothelin and isoprostanes in slow pressor responses to angiotensin II. Hypertension 37: 505-510, 2001.
118. Palmer RMJ, Ferrige AG, and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526, 1987.
119. Park F, Zou AP, and Cowley AW Jr. Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla. Hypertension 32: 896-901, 1998.
120. Patel KP, Li YF, and Hirooka Y. Role of nitric oxide in central sympathetic outflow. Exp Biol Med 226: 814-824, 2001.
121. Pelayo JC and Blantz RC. Analysis of renal denervation in the hydropenic rat: interactions with angiotensin II. Am J Physiol Renal Fluid Electrolyte Physiol 246: F87-F95, 1984.
122. 8]angiotensin II in the rat. Am J Physiol Renal Fluid Electrolyte Physiol 242: F149-F157, 1982.
123. Ploth DW, Rudulph J, LaGrange R, and Navar LG. Tubuloglomerular feedback and single nephron function after converting enzyme inhibition in the rat. J Clin Invest 64: 1325-1335, 1979.
124. Pollock DM, Polakowski JS, Divish BJ, and Opgenorth TJ. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition. Hypertension 21: 660-666, 1993.
125. Pollock DM and Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 281: F144-F150, 2001.
126. Price DA, Porter LE, Gordon M, Fisher ND, De'Oliveira JM, Laffel LM, Passan DR, Williams GH, and Hollenberg NK. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 10: 2382-2391, 1999.
127. Pryor WA and Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol Lung Cell Mol Physiol 268: L699-L722, 1995.
128. Quinn T and Burton J. Amino acid sequence of angiotensinogen as a basis for species-specificity of renin (Abstract). Chem Abst 97: 276, 1982.
129. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, and Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
130. Reckelhoff JF, Zhang H, Srivastava K, Roberts LJ 2nd, Morrow JD, and Romero JC. Subpressor doses of angiotensin II increase plasma F(2)-isoprostanes in rats. Hypertension 35:476-479, 2000.
131. Regoli D, Hess R, Brunner HB, Peters G, and Gross F. Interrelationship of renin content in kidneys and blood pressure in renal hypertensive rats. Arch Int Pharmacodyn Ther 140:416-426, 1962.
132. Roman RJ. Pressure-diuresis in volume-expanded rats. Tubular reabsorption in superficial and deep nephrons. Hypertension 12:177-183, 1988.
133. Romero JC, Feldstein AE, Rodriguez-Porcel MG, and Cases-Amenos A. New insights into the pathophysiology of renovascular hypertension. Mayo Clin Proc 72: 251-260, 1997.
134. Romero JC and Hoobler SW. The renin-angiotensin system in clinical medicine. Am Heart J 80: 701-708, 1970.
135. Romero JC and Knox FG. Mechanisms underlying pressure-related natriuresis: the role of the renin-angiotensin and prostaglandin systems. State of the art lecture. Hypertension 11: 724-738, 1988.
136. Romero JC, Lahera V, Salom MG, and Biondi ML. Role of the endothelium-dependent relaxing factor nitric oxide on renal function. J Am Soc Nephrol 2: 1371-1387, 1992.
137. Romero JC, Lazar JD, and Hoobler SW. Effects of renal artery constriction and subsequent contralateral nephrectomy on the blood pressure, plasma renin activity, and plasma renin substrate concentration in rabbits. Lab Invest 22: 581-587, 1970.
138. Romero JC and Reckelhoff JF. Role of angiotensin and oxidative stress in essential hypertension. Hypertension 34: 943-949, 1999.
139. Ruef J, Moser M, Kubler W, and Bode C. Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol 10: 311-315, 2001.
140. Salazar FJ, Alberola A, Pinilla JM, Romero JC, and Quesada T. Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition. Hypertension 22: 49-55, 1993.
141. Sasser JM, Pollock JS, and Pollock DM. Renal endothelin in chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol 283: R243-R248, 2002.
142. Sato Y, Ogata E, and Fujita T. Role of chloride in angiotensin II-induced salt-sensitive hypertension. Hypertension 18: 622-629, 1991.
143. Schnackenberg CG, Welch WJ, and Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 32: 59-64, 1998.
144. Schnackenberg CG and Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension 33: 424-428, 1999.
145. Schnackenberg CG, Wilkins FC, and Granger JP. Role of nitric oxide in modulating the vasoconstrictor actions of angiotensin II in preglomerular and postglomerular vessels in dogs. Hypertension 26: 1024-1029, 1995.
146. Schnermann J and Briggs J. Role of the renin-angiotensin system in tubuloglomerular feedback. Fed Proc 45: 1426-1430, 1986.
147. Schnermann J and Briggs JP. The Kidney: Physiology and Pathophysiology (2nd ed.), edited by Seldin DW and Giebisch G. New York: Raven, 1992.
148. Schnermann J and Briggs JP. Single nephron comparison of the effect of loop of Henle flow on filtration rate and pressure in control and angiotensin II-infused rats. Miner Electrolyte Metab 15: 103-107, 1989.
149. Schroder H and Schror K. Cyclic GMP stimulation by vasopressin in LLC-PK1 kidney epithelial cells is L-arginine-dependent. Naunyn Schmiedebergs Arch Pharmacol 340: 475-477, 1989.
150. Sealey JE, Catanzaro DF, Lavin TN, Gahnem F, Pitarresi T, Hu LF, and Laragh JH. Specific prorenin/renin binding (ProBP). Identification and characterization of a novel membrane site. Am J Hypertens 9: 491-502, 1996.
151. Seikaly MG, Arant BS Jr, and Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 86: 1352-1357, 1990.
152. Shoback DM, Williams GH, Moore TJ, Dluhy RG, Podolsky S, and Hollenberg NK. Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension. J Clin Invest 72: 2115-2124, 1983.
153. Sigmon DH, Carretero OA, and Beierwaltes WH. Angiotensin dependence of endothelium-mediated renal hemodynamics. Hypertension 20: 643-650, 1992.
154. Simon G, Illyes G, and Csiky B. Structural vascular changes in hypertension: role of angiotensin II, dietary sodium supplementation, blood pressure, and time. Hypertension 32: 654-660, 1998.
155. Sinaiko A and Mirkin BL. Ontogenesis of the renin-angiotensin system in spontaneously hypertensive and normal Wistar rats. Circ Res 34: 693-696, 1974.
156. Siragy HM, Howell NL, Ragsdale NV, and Carey RM. Renal interstitial fluid angiotensin. Modulation by anesthesia, epinephrine, sodium depletion, and renin inhibition. Hypertension 25: 1021-1024, 1995.
157. Skeggs LT, Lentz KE, Gould AB, Hochstrasser H, and Kahn JR. Biochemistry and kinetics of the renin-angiotensin system. Fed Proc 26: 42-47, 1967.
158. Smith JB. Angiotensin-receptor signaling in cultured vascular smooth muscle cells. Am J Physiol Renal Fluid Electrolyte Physiol 250: F759-F769, 1986.
159. Somers MJ, Mavromatis K, Galis ZS, and Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation 101: 1722-1728, 2000.
160. Staessen J, Bulpitt C, Fagard R, Lijnen P, and Amery A. Long-term converting-enzyme inhibition as a guide to surgical curability of hypertension associated with renovascular disease. Am J Cardiol 51: 1317-1322, 1983.
161. Steiner RW, Tucker BJ, and Blantz RC. Glomerular hemodynamics in rats with chronic sodium depletion. Effect of saralasin. J Clin Invest 64: 503-512, 1979.
162. Stoos BA, Carretero OA, and Garvin JL. Endothelium-derived relaxing factor inhibits transport in cultured cortical collecting duct cells (Abstract). Hypertension 18: 390, 1991.
163. Stroes E, Hijmering M, van Zandvoort M, Wever R, Rabelink TJ, and van Faassen EE. Origin of superoxide production by endothelial nitric oxide synthase. FEBS Lett 438: 161-164, 1998.
164. Svetkey LP, Himmelstein SI, Dunnick NR, Wilkinson RH Jr, Bollinger RR, McCann RL, Beytas EM, and Klotman PE. Prospective analysis of strategies for diagnosing renovascular hypertension. Hypertension 14: 247-257, 1989.
165. Swales JD, Thurston H, Queiroz FP, Medina A, and Holland J. Dual mechanism for experimental hypertension. Lancet 2: 1181-1184, 1971.
166. Szentivanyi M, Zou AP, and Cowley AW Jr. Hypertensive effects of angiotensin II in Dahl S rats is enhanced by reduced responsiveness of the renal medullary NO system (Abstract). FASEB J 13: A783, 1999.
167. 2α, in the rat. Evidence for interaction with thromboxane A2 receptors. J Clin Invest 90: 136-141, 1992.
168. Tarpey MM and Fridovich I. Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 89: 224-236, 2001.
169. Terada Y, Tomita K, Nonoguchi H, and Marumo F. PCR localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney. Kidney Int 43: 1251-1259, 1993.
170. Traylor TG and Sharma VS. Why NO? Biochemistry 31: 2847-2849, 1992.
171. Upmacis RK, Deeb RS, and Hajjar DP. Regulation of prostaglandin H2 synthase activity by nitrogen oxides. Biochemistry 38: 12505-12513, 1999.
172. Usui M, Egashira K, Kitamoto S, Koyanagi M, Katoh M, Kataoka C, Shimokawa H, and Takeshita A. Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 34: 546-551, 1999.
173. Vallance P, Collier J, and Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2: 997-1000, 1989.
174. Van Kats JP, de Lannoy LM, Jan Danser AH, van Meegen JR, Verdouw PD, and Schalekamp MA. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 30: 42-49, 1997.
175. Van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, and Danser AH. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 60: 2311-2317, 2001.
176. Vasquez-Vivar J, Hogg N, Martasek P, Karoui H, Pritchard KA Jr, and Kalyanaraman B. Tetrahydrobiopterin-dependent inhibition of superoxide generation from neuronal nitric oxide synthase. J Biol Chem 274: 26736-26742, 1999.
177. Vaziri ND, Wang XQ, Oveisi F, and Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36: 142-146, 2000.
178. Welch WJ, Tojo A, and Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol 278: F769-F776, 2000.
179. Welch WJ and Wilcox CS. AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR. Kidney Int 59: 1257-1263, 2001.
180. Wever RM, van Dam T, van Rijn HJ, de Groot F, and Rabelink TJ. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 237: 340-344, 1997.
181. Wilcox CS and Welch WJ. Macula densa nitric oxide synthase: expression, regulation, and function. Kidney Int Suppl 67: S53-S57, 1998.
182. Wong PC, Price WA Jr, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, and Timmermans PB. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X. Hypertension 15: 459-568, 1990.
183. Wood JM. Current Advances in ACE Inhibition 2, edited by MacGregor GA and Severs PS. London: Churchill Livingstone, 1991.
184. Wright FS and Briggs JP. Feedback control of glomerular blood flow, pressure, and filtration rate. Physiol Rev 59: 958-1006, 1979.
185. Wu F, Park F, Cowley AW Jr, and Mattson DL. Quantification of nitric oxide synthase activity in microdissected segments of the rat kidney. Am J Physiol Renal Physiol 276: F874-F881, 1999.
186. Wu R, Millette E, Wu L, and de Champlain J. Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J Hypertens 19: 741-748, 2001.
187. 2+/calmodulin-dependent and tetrahydrobiopterin regulatory process. J Biol Chem 273: 25804-25808, 1998.
188. 1-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 282: C926-C934, 2002.
189. Yamaguchi Y, Fenoy FJ, Roman RJ, and Nasjletti A. Angiotensin II influences the renal hemodynamic response to blockade of thromboxane A2 and prostaglandin H2 receptors. J Pharmacol Exp Ther 263: 905-909, 1992.
190. Ylitalo P and Gross F. Hemodynamic changes during the development of sodium-induced hypertension in subtotally nephrectomized rats. Acta Physiol Scand 106: 447-455, 1979.
191. Zanzinger J and Czachurski J. Chronic oxidative stress in the RVLM modulates sympathetic control of circulation in pigs. Pflügers Arch 39: 489-494, 2000.
192. 2-Adrenergic receptor-mediated increase in NO production buffers renal medullary vasoconstriction. Am J Physiol Regul Integr Comp Physiol 279: R769-R777, 2000.
193. Zou AP and Cowley AW Jr. Nitric oxide in renal cortex and medulla. An in vivo microdialysis study. Hypertension 29: 194-198, 1997.
194. Zou AP, Wu F, and Cowley AW Jr. Protective effect of angiotensin II-induced increase in nitric oxide in the renal medullary circulation. Hypertension 31: 271-276, 1998.
195. Zou M, Martin C, and Ullrich V. Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol Chem 378: 707-713, 1997.